October 19, 2023 9:27am

100 employees, or 20% of its current workforce, as part of a restructuring plan

BEAM closed down -$1.47 or -6.60% to $20.80 with a negative -$0.41 or -1.97% pre-open indication

BEAM will focus on developing its experimental sickle cell disease treatment and its program for alpha-1 antitrypsin deficiency (AATD), a condition that raises risk for lung and other diseases.

Beam expects the cost savings from the plan, and its balance of cash and equivalents of $1.1 billion as of June 30, would be sufficient to fund operations into 2026.


The Bottom Line: Sign of the times … headcount reductions, strategic reorganization … Related to the workforce reduction, BEAM expects to incur one-time costs of approximately $6.6 million, of which nearly all are cash expenditures related to severance and are anticipated to be incurred in the fourth quarter of 2023.

  • Decisions of pipeline programs:
  • Prioritize development of its ex vivo and in vivo sickle cell disease programs, including BEAM-101, its Engineered Stem Cell Antibody Paired Evasion (ESCAPE) non-genotoxic conditioning strategy, and in vivo delivery to hematopoietic stem cells (HSCs).
  • Prioritize development of its in vivo base editor BEAM-302 for the treatment of alpha-1 antitrypsin deficiency (AATD).
  • Conduct an initial BEAM-301 clinical trial for the treatment of glycogen storage disease 1a (GSD1a) at a select number of sites in the United States.
  • Generate a focused clinical dataset for BEAM-201 for the treatment of T-ALL and seek potential partnership for this and other potential ex vivo CAR-T programs, including Beam’s ongoing research into creating next-generation allogeneic cell therapies with multiplex base editing.


I hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I am more frequently right than consequentially wrong but, I am mostly EARLY!


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.


Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.